机译:P1.13-44在NSCLC中口服EGFR / HER2外显子20抑制剂TAK-788的安全性,PK和初步抗肿瘤活性
Medicine (Oncology) Stanford Cancer Intitute/stanford University Stanford/CA/US;
University of Colorado Cancer Center Aurora/CO/US;
Memorial Sloan Kettering Cancer Center New York/NY/US;
Virginia Cancer Specialists Fairfax/VA/US;
Vanderbilt-Ingram Cancer Center Nashville/TN/US;
Massachusetts General Hospital Boston/MA/US;
Beth Israel Deaconess Medical Center Boston/MA/US;
Millennium Pharmaceuticals Inc. A Wholly Owned Subsidiary of Takeda Pharmaceutical Company;
Millennium Pharmaceuticals Inc. A Wholly Owned Subsidiary of Takeda Pharmaceutical Company;
Millennium Pharmaceuticals Inc. A Wholly Owned Subsidiary of Takeda Pharmaceutical Company;
Millennium Pharmaceuticals Inc. A Wholly Owned Subsidiary of Takeda Pharmaceutical Company;
Millennium Pharmaceuticals Inc. A Wholly Owned Subsidiary of Takeda Pharmaceutical Company;
Dana-Farber Cancer Institute Boston/MA/US;
机译:P1.13-44在NSCLC中口服EGFR / HER2外显子20抑制剂TAK-788的安全性,PK和初步抗肿瘤活性
机译:EGFR和HER2外显子20插入到共价EGFR和HER2抑制剂的响应异质性
机译:P2.13-32 TAK-788是一种新颖和有效的酪氨酸激酶抑制剂,具有针对EGFR / HER2的选择性活动
机译:NSCLC中的Mobocertinib(TAK-788)聚焦具有EGFR外显子20插入突变
机译:P1.13-44在NSCLC中口服EGFR / HER2外显子20抑制剂TAK-788的安全性,PK和初步抗肿瘤活性